MetaVia's AI-Driven Analysis Confirms Vanoglipel's Therapeutic Targets for MASH and Type 2 Diabetes
Key Insights
MetaVia (search)'s collaboration with Syntekabio (search) using AI-based compound-protein interaction modeling has identified key inflammatory and cardiometabolic targets for vanoglipel (search) (DA-1241), supporting its development for MASH (search) and type 2 diabetes (search).
The DeepMatcher® platform analysis highlighted inflammatory diseases, cardiometabolic disorders, and cancer (search) as top predicted target areas, with cancer identification linked to strong inflammation reduction in AI-predicted pathways.
Vanoglipel (search) demonstrated direct hepatic activity and favorable safety profile in a Phase 2a study of 109 patients over 16 weeks, reinforcing confidence in the drug's broader therapeutic potential.
MetaVia (search) Inc. has announced positive results from its ongoing artificial intelligence collaboration with Syntekabio (search), providing computational validation for the therapeutic targets of its lead cardiometabolic drug candidate vanoglipel (search) (DA-1241). The AI-driven analysis confirms the compound's engagement with key inflammatory and metabolic pathways, supporting its continued development for metabolic dysfunction-associated steatohepatitis (search) (MASH (search)) and type 2 diabetes (search).
AI Platform Identifies Key Therapeutic Pathways
Using Syntekabio (search)'s proprietary DeepMatcher® platform, researchers conducted AI-based compound-protein interaction modeling to identify disease targets for vanoglipel (search), an oral G-protein-coupled receptor 119 (GPR119 (search)) agonist. The analysis highlighted inflammatory diseases, cardiometabolic disorders, and cancer (search) as the top predicted target areas, directly aligning with MetaVia (search)'s therapeutic focus.
"The AI modeling results provide strong confirmation that vanoglipel (search) engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis (search) (MASH (search)) and potential type 2 diabetes (search) (T2D)," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia (search).
The identification of cancer (search)-related pathways was particularly notable, as it was linked to the strong reduction in inflammation observed in AI-predicted target pathways, suggesting broader anti-inflammatory potential for the compound.
Clinical Evidence Supports AI Predictions
The computational findings align with clinical data from MetaVia (search)'s Phase 2a study, which demonstrated vanoglipel (search)'s direct hepatic activity and improvements in glucose metabolism. The trial enrolled 109 patients over 16 weeks and showed a favorable safety and tolerability profile alongside therapeutic efficacy.
Kim emphasized that these combined insights from AI modeling and clinical results "give us confidence in DA-1241's broader therapeutic potential." The company plans to continue leveraging the Syntekabio (search) AI platform to explore additional indications and further optimize vanoglipel (search)'s therapeutic profile.
Mechanism of Action and Preclinical Data
Vanoglipel (search) functions as a GPR119 (search) agonist with development potential as both standalone and combination therapy for MASH (search) and type 2 diabetes (search). The compound's mechanism involves promoting the release of key gut peptides GLP-1, GIP, and PYY, which play crucial roles in glucose metabolism, lipid metabolism, and weight loss.
In multiple preclinical animal models of MASH (search) and type 2 diabetes (search), vanoglipel (search) demonstrated significant therapeutic effects, reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control. The compound showed beneficial effects on glucose levels, lipid profiles, and liver inflammation across various in vivo studies.
Clinical Development Program
Vanoglipel (search) has progressed through Phase 1a, 1b, and 2a trials, demonstrating good tolerability in both healthy volunteers and patients with type 2 diabetes (search) mellitus. The Phase 2a clinical study specifically showed direct hepatic action in addition to glucose-lowering effects, supporting the compound's dual therapeutic potential.
The collaboration with Syntekabio (search) represents part of MetaVia (search)'s broader strategy to leverage artificial intelligence in drug development. Syntekabio, a KOSDAQ-listed company (226330), has been integrating biology with AI and machine learning since 2009, offering drug discovery services from target identification through IND-enabling studies using its proprietary supercomputer cloud and global contract research organization network.